User: Guest  Login
Title:

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas.

Document type:
Journal Article
Author(s):
Bunse, Lukas; Rupp, Anne-Kathleen; Poschke, Isabel; Bunse, Theresa; Lindner, Katharina; Wick, Antje; Blobner, Jens; Misch, Martin; Tabatabai, Ghazaleh; Glas, Martin; Schnell, Oliver; Gempt, Jens; Denk, Monika; Reifenberger, Guido; Bendszus, Martin; Wuchter, Patrick; Steinbach, Joachim P; Wick, Wolfgang; Platten, Michael
Abstract:
INTRODUCTION: Isocitrate dehydrogenase (IDH) mutations are disease-defining mutations in IDH-mutant astrocytomas and IDH-mutant and 1p/19q-codeleted oligodendrogliomas. In more than 80% of these tumors, point mutations in IDH type 1 (IDH1) lead to expression of the tumor-specific protein IDH1R132H. IDH1R132H harbors a major histocompatibility complex class II (MHCII)-restricted neoantigen that was safely and successfully targeted in a first-in human clinical phase 1 trial evaluating an IDH1R132H...     »
Journal title abbreviation:
Neurol Res Pract
Year:
2022
Journal volume:
4
Journal issue:
1
Fulltext / DOI:
doi:10.1186/s42466-022-00184-x
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/35599302
TUM Institution:
Klinik und Poliklinik für Neurochirurgie
 BibTeX